OXiGENE To Focus Ophthalmology Strategy Toward Non-Invasive Administration Of CA4P For Age-Related Macular Degeneration (AMD); Closes Enrollment Of Phase II CA4P Clinical Trial In Myopic Macular Degeneration (MMD-213)

WALTHAM, Mass.--(BUSINESS WIRE)--Sept. 12, 2006--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it is planning to focus its ophthalmology strategy on oral or other non-intravitreal forms of administrations of Combretastatin A4 Phosphate (CA4P) for age-related macular degeneration (AMD).